Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):182–188. doi: 10.1097/QAI.0000000000003033

Fig. 1.

Fig. 1.

Observed pre-dose concentrations of 10–1074 and VRC01LS at 28 days following single and dual bNAb administration. Lines connect the values from participants evaluated in both Phase A and B.